Law

Sam Bankman-Fried lacks cover of systemic risk

13 Dec 2022

The former boss of bankrupt crypto firm FTX has been arrested. That hasn’t happened to financial hall-of-shamers that are more mainstream. The decentralised nature of crypto makes isolating people easier. The more complex the institution or blow-up, the harder it is to pin blame.

Big Pharma’s heartburn win is a valuation salve

7 Dec 2022

GSK, Haleon and Sanofi’s combined worth rose $14 bln after a U.S. judge dismissed claims that a drug causes cancer. It frees up cash for new research and deals. The victory also helps lay to rest the ghost of Bayer’s Roundup legal thwack, which has haunted the sector since 2020.

FTX flop evokes history’s great financial swindles

18 Nov 2022

Investment bubbles are generally accompanied by fraud. The collapse of Sam Bankman-Fried’s cryptocurrency exchange has elements of past scandals, from Dutch tulip mania to Bernie Madoff. Unusually, the 30-year-old seems to have previewed his own downfall, says Edward Chancellor.

Stephen King makes for unlikely antitrust hero

1 Nov 2022

A U.S. judge blocked Penguin’s $2.2 bln deal with rival publisher Simon & Schuster, after watchdogs argued it would unfairly limit pay for top authors. If the decision sticks, future mergers may be vetted based on their effect on workers as well as customers. It could get messy.

Credit Suisse legal tab is wildcard for investors

17 Oct 2022

The bank settled an old mortgage case without having to set more money aside. But the bill for future litigation, up to $1.6 bln on its own estimates, will erode earnings. The risk for investors in a looming rights issue is that further nasties bog down the bank’s restructuring.

Guest view: Russia sanctions lack decisive punch

27 Sep 2022

Restrictions imposed by the United States and its allies following President Vladimir Putin’s invasion of Ukraine have done economic damage, write William Rhodes and Stuart Mackintosh. But Cuba and Iran show American sanctions are not decisive in changing geopolitical outcomes.

U.S. drug price cap hurts Big Pharma twice over

15 Sep 2022

President Biden’s plan to curb medicine bills could cost drugmakers like Pfizer or GSK $29 bln a year in lost sales. To cope, companies may focus on blockbuster therapies, and shun niche treatments. More competition in hot areas like cancer may mean lower prices and poor returns.

Long arm of China law reaches today from Tomorrow

22 Aug 2022

Xiao Jianhua, the man behind the dismembered investment colossus, has been convicted of graft and illegal use of funds five years after he was snatched from Hong Kong. His fate is a timely reminder that Beijing is determined to show that no company or person is too big to fail.

Big Pharma should brace for worst cancer outcome

18 Aug 2022

Investors have wiped $36 bln off Sanofi, GSK and its consumer spinoff on fears heartburn remedies cause cancer. The science implies an overreaction. But the scope for U.S. juries to see the saga as akin to Bayer’s Roundup weedkiller debacle could actually make the hit bigger.

Capital Calls: Illumina, Peloton

12 Aug 2022

Concise views on global finance: Growth is stagnating at the $30 bln DNA sequencing company, and regulatory problems with its Grail deal are also coming into view; a class action lawsuit against the virtual fitness outfit provides an unlikely reminder of its former glory days.

UK’s Bain ban sets oddly high moral bar

3 Aug 2022

Britain has barred the consultancy from public contracts due to misconduct in South Africa. The nod to ethics is overdue but tricky. Rivals McKinsey and KPMG, hit by related scandals, escaped UK censure. A similar stand against global skulduggery would red-card much of the City.

Review: The cat and mouse game of Russia sanctions

15 Jul 2022

In “Freezing Order”, investor Bill Browder describes lobbying to suspend the assets of those responsible for the death of his Russian employee. Moscow used economic interests and U.S. lawyers to undermine the sanctions. The same tactics threaten the response to the Ukraine war.

American shipping law doesn’t sail

27 Jun 2022

A U.S. act passed in 1920 requires ships traveling between U.S. ports to be American made and operated. But that has doubled the cost of transporting gas from Houston to New York, among other things. Eliminating the old rule would ease pressures on shortages – and rising prices.

Casino SPAC is for hardened gamblers only

7 Jun 2022

A legal battle over Okada Manila resort turned physical when its ousted boss seized the property last week. That could scupper its $2.7 bln deal with a U.S. blank-cheque firm. But unfriendly politicians, dubious financial reports and more stack the odds against investors, too.

Capital Calls: Airbnb, Prudential, Glencore

25 May 2022

Concise views on global finance: The $68 bln vacation-booking platform will shut its Chinese business; the insurer appoints a new CEO – finally; the commodities giant has a $10 bln reason to keep its nose clean, after a $1.5 bln settlement for corruption allegations.

Xiaomi fight puts China Inc on India red alert

13 May 2022

The country’s tax and financial agencies have tried to block some $1.2 bln of the smartphone maker’s funds. New Delhi engaged Vodafone, Cairn and others in similar battles but its testy relations with Beijing up the ante. Xiaomi and Chinese peers in India face a slow decline.

Capital Calls: Coinbase is conjoined to crypto

11 May 2022

Concise views on global finance: The exchange saw users and volumes fall, revenues slashed and lost over $400 mln in the first quarter. When cryptocurrencies slump, Coinbase has no choice but to follow.

Post Roe-leak, it’s not the economy, stupid

6 May 2022

Republicans were in a sweet spot ahead of November’s U.S. elections. Joe Biden’s early presidency has brought inflation, a failed attempt to tax the rich, and little help for the middle class. A leaked Supreme Court opinion on abortion, though, changes the calculus.

EU’s oil embargo is slave to volatile crude price

4 May 2022

The bloc wants to stop buying Russian exports within six months. That looks too slow to properly choke off funding for President Vladimir Putin’s war machine. Yet going any faster could make crude prices spike, exacerbating Europe’s battle against inflation.

China’s “bulletproof” coffee IPO is full of holes

12 Apr 2022

Star Plus Legend banks on the founder's pop-star son, Jay Chou, hawking butter-infused, or bulletproof, java and other diet fads. Beijing's crackdown on celebrity influence, however, threatens $57 mln of revenue. Using consumers as a sales force raises another red flag.